Compare Dolby Laboratories, Inc. (DLB) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs Nuwellis Inc — how do they compare? Dolby Laboratories, Inc. trades at $48.49 (market cap $4.59B), while Nuwellis Inc trades at $3.35 (market cap $1.17M). The key difference: Dolby Laboratories, Inc. is far larger — about 3923.1× Nuwellis Inc's market cap, and Dolby Laboratories, Inc. pays a 2.91% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| DLB | NUWE | |
|---|---|---|
Market Cap | $4.59B | $1.17M |
Sector | Industrials | Technology |
52-Week High | $76.79 | $558.26 |
52-Week Low | $48.51 | $2.80 |
Enterprise Value | $4.04B | -$636.97K |
Dividend Yield | 2.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dolby Laboratories (DLB) trades at $49.36, down 0.88% on the day, with a bearish technical outlook. The company maintains strong fundamentals, including a P/E of 19.59, a net income margin of 17.85%, and consistent earnings beats in recent quarters. Recent news highlights include its role in powering immersive audio for the FIFA World Cup 2026 coverage and recognition as a top supplier by General Motors.
The stock presents a value opportunity given its discount to the analyst consensus price target of $87.50, but faces near-term headwinds from bearish technical signals and cyclical end-market exposure. Upside potential hinges on continued licensing growth and execution, while risks include market sentiment and competitive pressures.
NUWE trades at $2.80, down 7.89% in the last session, with a bearish technical outlook from moving averages. The company reported a net loss of $17.52 million in 2025 despite $8.27 million revenue, reflecting a negative net margin of 217.22%. Recent developments include a CEO transition to Mike McCormick, a $6 million public offering in June 2026, and expansion in pediatric care installations, indicating strategic growth efforts amid financial challenges.
The outlook remains high-risk due to persistent losses and negative ROE/ROA, though low P/E and P/B ratios suggest undervaluation. Analyst sentiment is split evenly between buy and hold. Key risks include cash burn from negative operating cash flow and execution hurdles in scaling commercial adoption. Upside depends on revenue acceleration and cost management under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
